Clinical Trial Update: Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluates axicabtagene ciloleucel as second-line therapy for relapsed/refractory aggressive B-cell lymphoma in patients ineligible for …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive B-cell Lymphoma
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Yescarta (axicabtagene ciloleucel)

Snippet

Sponsor: The Lymphoma Academic Research Organisation | Conditions: B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent | Phase 2 | Status: ACTIVE_NOT_RECRUITING